Lymphoma 2) is also upregulated by IL-2 at the most mature DP stage. In addition to IL-2, we identify IL-15 to have a significant role in the upregulating FOXP3 and survival of Tregs at the DP phase. IL-7 also increases the expression of BCL-2 in the DP FOXP3 + thymocytes. Our results indicate that common gamma chain cytokines IL-2, IL-7 and IL-15 promote the development of regulatory T cells at the most mature DP stage after TCR-mediated positive selection through suppressing cell death.
| INTRODUCTION
The role of regulatory T cells in controlling immune responses is essential for the maintenance of immunological tolerance and prevention of autoimmunity. The main population of Tregs is characterized by the expression of the forkhead/winged-helix transcription factor FOXP3, which promotes and stabilizes the regulatory phenotype. Mutations in FOXP3 result in developmental and functional abnormalities in the Treg population, and lead to early and severe immune dysregulation, polyendocrinopathy, enteropathy and X-linked syndrome (IPEX) in humans. 1 In contrast to peripherally induced Tregs, most FOXP3 + Tregs are thought to arise in the thymus as a distinct T cell lineage, and are therefore often referred to as natural Tregs. 2, 3 Their development in the thymus has been extensively studied in murine models. 4 Based on these studies, the prevalent view holds that commitment to the Treg lineage takes place at the CD4 + single-positive (SP) stage, 5 but the existing evidence in humans suggests an earlier point of divergence. 6, 7 TCR-mediated signals are essential for T cell development, and intermediate-to-high affinity interactions with self-antigens may favour Treg commitment. [8] [9] [10] Several cytokines have been shown to play a role, as well, and common gamma chain cytokines in particular seem to be important. 11, 12 Natural Tregs express constitutively high levels of CD25, the alpha chain of IL-2 receptor, and IL-2 has been shown to be crucial for Treg homeostasis and function in the periphery. [13] [14] [15] In mice, IL-2 induces the activation of STAT5, promotes Foxp3 and CD25 expression and drives Treg development in the thymus. 16, 17 IL-2-, IL-2Rα-and IL-2Rβ-deficient mice manifest severe autoimmunity and their number of Tregs is reduced, 5, 18 whereas transgenic IL-2Rβ expression in the thymus of IL-2Rβ-deficient mice restores the Treg production and prevented autoimmune disease. 19 The administration of anti-IL-2 antibodies also reduces the number of thymic Tregs. 20 In contrast, IL-15-deficient mice do not exhibit lethal autoimmunity disease. 16 However, several reports suggest that it promotes murine Treg development, though to a lesser degree than IL-2.
12,21
Despite the murine studies, human thymic Treg maturation remains only partially understood. There are notable differences between human and murine Treg development. These include the timing of commitment, which in humans seems to start already at the CD4 25 In the present study,
we have investigated the effects of IL-2, IL-7 and IL-15 on the critical FOXP3 + DP population.
| MATERIALS AND METHODS

| Patient samples
Thymic tissue was obtained from altogether 40 otherwise healthy children (19 boys, 21 girls) undergoing corrective cardiac surgery. The children were from 0.0 to 10.8 years old (mean 2.0 year, median 0.5). The pediatric ethics committee of Helsinki University Hospital approved the study. Informed consent was obtained from the parents.
| Cell isolation, flow cytometry
Thymocytes were isolated within 6 hours of the thymectomy from the tissue samples by mechanical homogenization. The antibodies used in the experiments were direct fluorochrome conjugates: CD8-PE-Cy7, CD8-APC, CD4-APC-Cy7, FOXP3-APC, CD5-PerCPCy5. 
| Cell culture and quantitative PCR
Thymocytes were cultured in a 12-well plate with human cell culture media (RPMI, 10% hAB serum, 1% 100× penicillin-streptomycin, 1% HEPES, 0.1% L-glutamine, 0.1% MeEtOH) overnight. IL-2, IL-15 and IL-7 was purchased from Immunotools and used at a final concentration of 25 ng/mL (IL-2) and 10 ng/mL (IL-15 and IL-7). 25 Stimulation with anti-CD3 mAb was done in solution. The cells were incubated for 10 minutes on ice with 1 μg anti-CD3/ 5 × 10 6 cells, followed by cross-linking with 4 μg goatanti-mouse IgG (both purchased from Immunotools). Apoptosis detection was done using the apoptosis staining kit with Annexin and PI (Beckton Dickinson) according to manufacturer's instructions. Since permeabilization cannot be used with the apoptosis staining, Treg-associated marker CD25 was used instead of FOXP3. Total RNA was isolated with RNeasy MiniKit according to the manufacturer's instructions (Qiagen, Hilden, Germany) and first-strand cDNA was synthesized using oligo-dT-primer (Sigma) and AMV-reverse transcriptase (Finnzymes, Helsinki, Finland). The mRNA level of FOXP3 was quantified using Taqman Universal Master Mix (applied Biosystems) and Bio-Rad iCycler (Hercules, CA). The quantitative PCR data were normalized against B-actin expression levels. The primer-probe sets for FOXP3 and B-actin were bought from Applied Biosystems.
| Statistical analysis
Statistical analysis was done with SPSS and GraphPad Prism software. The results are presented as arithmetic mean and standard deviations. P-values for differences were calculated using Student′s two-tailed paired t test. P-value <0.05 was considered significant.
| RESULTS
| IL-2 promotes Treg development at the
DP stage
IL-2 and IL-15 have been recently suggested to be the main cytokines enhancing Treg commitment. 25 The emphasis of these studies was on the CD4SP stage, but FOXP3 upregulation was also reported at the DP stage. Since the commitment to the regulatory lineage in humans starts already at the DP stage, 6, 7 we analysed in detail the role of IL-2 in the development of FOXP3 + DP cells.
Thymocytes were cultured overnight with or without exogenously added IL-2. In general, stimulation with IL-2 produced a significant increase in the FOXP3 mRNA level in the thymocyte population. The relative amount of FOXP3 mRNA was measured with quantitative PCR, using beta-actin to normalize the data. In the presence of IL-2, the mean delta Ct value of FOXP3 mRNA increased from −2.2 ± 5.0 to −0.3 ± 4.9 (P < 0.01, n = 7) ( Figure 1A 1.0% ± 0.6% (P < 0.01, n = 6), while the MFI increased from 35.6 ± 13.9 to 44.1 ± 16.3 (P < 0.05). IL-2 also upregulated the expression of Treg-associated markers CTLA-4 (cytotoxic T-lymphocyte-associated molecule-4) and CD25. Within the FOXP3 + DP population, the expression of intracellular CTLA-4 increased from 9.3% ± 1.6% to 13.2% ± 2.6% (P < 0.01, n = 8) and the CTLA-4 MFI from 156.6 ± 16.3 to 182.0 ± 22.4, P < 0.05) (Figure 2A-B) . Likewise, the frequency of CD25 + cells in the DP population increased from 0.3% ± 0.1% to 0.6% ± 0.3% (P < 0.05, n = 8) and CD25 MFI from 36.1 ± 4.3 to 63.1 ± 16.7 (P < 0.01
Thus, exposure to IL-2 at the DP stage both upregulates the expression of FOXP3 and promotes Tregassociated markers and Treg phenotype.
| IL-2 influences selectively the most mature DP cells
Consecutive steps of the development at the DP stage are associated with the initiation and upregulation of TCR expression. To analyse in more detail the effects of IL-2, we subdivided by gating the DP thymocytes into 3 maturation stages based on CD3 expression levels. At the earliest stage, thymocytes lack the CD3 molecule on their surface but start to express it at the CD3 low phase. The transition to the CD4SP stage takes place after the most mature DP CD3 Figure 3A) . Thus, IL-2 has the potential to influence the developing thymocytes at least from the DP CD3 low stage onwards. 18.1% ± 22.6) and IL-2 had no effect on cell proliferation. The DP cells are also subject to TCR-mediated selection, and IL-2 might modulate TCR-signalling and thus promote Treg maturation. To analyse whether IL-2 changes the outcome of the stimulation through TCR/CD3-complex, we cocultured the cells with anti-CD3 mAb and IL-2. This increased the frequency of FOXP3 + cells in the DP population from 0.3% ± 0.3% to 0.8% ± 0.8% (n = 6, P < 0.05) (Figure 4B) . However, this increase did not differ significantly from the effects of IL-2 stimulation alone (0.8% ± 0.7%).
| Interleukin-2 promotes FOXP3 + DP cell survival
We have previously shown that IL-7 protects DP CD25 + thymocytes from apoptosis, 7 and analysis of Annexin V/ propidium iodide staining showed that IL-2 has the same effect, as well. In these experiments, the surface marker CD25 instead of FOXP3 was used, since permeabilization of the cells is not compatible with detection of apoptotic cells. The overnight culture with IL-2 decreased the frequency of Annexin V+PI+ late apoptotic/necrotic cells within the CD25 + DP population from 50.5% ± 20.4% to 33.1% ± 18.5% (n = 11, P < 0.001) ( Figure 5A-B) . In the CD25-DP subset, very few apoptotic cells were observed, and IL-2 had no detectable effect. The frequency of nonapoptotic Annexin V-PI-cells was 91.4% ± 8.5% without and 91.2% ± 8.3% with IL-2 in the cell culture. The DP CD25 + thymocytes were thus highly susceptible to cell death but IL-2 promoted their survival.
We then measured the effects of IL-2 on the expression of the major anti-apoptotic protein BCL-2 (B-Cell Lymphoma 2). In accordance with earlier reports, 27,28 BCL-2 expression is sharply downregulated at the transition from DN to DP stage, decreasing from 74.9% ± 10.2% to 15.5% ± 12.9%. However, the frequency of BCL-2 in the DP FOXP3 + subset was significantly higher (66.5% ± 17.0%), with an increasing trend in subsequent maturation stages (from 29.3% ± 22.5% at the DP CD3 neg stage to 87.4% ± 7.3% at the CD3 high stage) ( Figure 5C ).
There was also a clear inverse correlation with cell proliferation, with most of the DP FOXP3 + cells expressing either BCL-2 or Ki-67 but not both ( Figure 5D ). The mean frequency of BCL-2 + Ki-67 + DP FOXP3 + cells was 3.6% ± 1.9%.
Overnight culture with IL-2 induced a clear increase in the expression of BCL-2 in the DP FOXP3 + population, observed both in the frequency of BCL-2 + cells (32.0% ± 19.0% vs 49.6% ± 24.3%, P < 0.01, n = 10) and BCL-2 MFI (175.7 ± 60.2 vs 246.9 ± 33.7, P < 0.05) ( Figure 5E-F) . In the DP FOXP3-counterparts, the expression of BCL-2 was low (4.3% ± 2.9%) and IL-2 induced a minor increase in the frequency but not in MFI.
Since the effects of IL-2 seemed to affect specifically the most mature CD3 high DP FOXP3 + cells ( Figure 3B ), we next analysed the IL-2-induced changes in BCL-2 expression at the different maturation stages. Again, the effects were most prominent in the FOXP3 + DP CD3 high stage, in which culture with IL-2 increased BCL-2 frequency from 57.5% ± 25.0% to 64.0% ± 26.1% (P < 0.05, n = 10) and BCL-2 MFI from 156.8 ± 47.6 to 227.9 ± 32.1 (P < 0.01) ( Figure 7A ). At the CD3 low stage, IL-2 had no significant effect on the frequency of the BCL-2 but it increased BCL-2 MFI from 172.0 ± 53.3 to 226.8 ± 53.4 (P < 0.05) ( Figure 7B ). At the CD3 neg stage, IL-2 had no effect on BCL-2 expression. IL-2 had also some effect on FOXP3-DP cells at the CD3 high stage, increasing BCL-2 frequency from 36.4% ± 18.8% to 43.1% ± 19.4% (P < 0.05) but not MFI. Together, these data show that IL-2 induces anti-apoptotic BCL-2 and protects DP FOXP3 + cells from cell death, especially at most mature DP CD3 high stage.
| Other common gamma chain cytokines also promote FOXP3 + DP cell survival
In addition to IL-2, the common gamma-chain cytokine IL-15 has also been shown to promote human Treg maturation. 25 Overnight culture with exogenous IL-15 increased the frequency of DP FOXP3 + cells from 0.4% ± 0.3% to 0.8% ± 0.6% (P < 0.05, n = 8) and FOXP3 MFI from 22.2 ± 4.1 to 27.4 ± 4.7 (P < 0.01) ( Figure 6A-B) . Similarly to IL-2, the most significant increase was seen at the DP CD3 high stage (from 1.2% ± 0.8% to 3.0% ± 2.7%; P < 0.05, n = 8 and MFI from 18.8 ± 4.4 to 25.0 ± 8.8, P < 0.01). No significant increase of FOXP3 expression was detected at the earlier DP stages. IL-15 also induced a decrease of late apoptotic/necrotic Annexin V+ PI+ cells from 50.5% ± 20.4% to 29.7% ± 20.7% (n = 11, P < 0.001) ( Figure 6C ). The expression of BCL-2 increased, as well (from 24.5% ± 16.1% to 34.5% ± 16.5%; P < 0.05, n = 7) ( Figure 6D -E), but to a lesser degree than observed with IL-2, and there was no significant effect on BCL-2 MFI. Moreover, in contrast to the effects of IL-2, the increase in BCL-2 frequency was observed in the FOXP3 + DP CD3 low cells (14.8% ± 15.2% to 21.3% ± 14.9%, P < 0.05) and not in the CD3 high cells ( Figure 7B ). We have previously reported that IL-7 promotes the Treg phenotype and protects FOXP3 + cells from apoptosis at the DP stage in the human thymus. 7 To see whether the effects of IL-7 on BCL-2 were similar to IL-2, we analysed BCL-2 expression in the thymocyte culture with and 
| DISCUSSION
The developmental pathway of human regulatory T cells is still only partly known, and seems to differ in some details from that in the murine thymus. It should be noted that our identification of thymocytes in the Treg lineage was based on the expression of FOXP3. Although in murine models Treg development has been shown to be possible in the absence of functional FoxP3, 29 during normal T cell maturation the upregulation of FOXP3 is associated with commitment to the Treg lineage. In the periphery, FOXP3 can also be transiently expressed in activated by non-regulatory T cells, but at the immature DP stage of thymocyte development this is not likely to be a significant confounding factor. Thus, the expression of FOXP3 can be used as a reasonable proxy to track the maturation of thymic natural Tregs.
In In addition to TCR stimulation, several cytokines are important to the maturation of Treg cells. Although some cytokines, such as IL-7, influence the early T cell development and thus indirectly also Tregs, the specific impact on the Treg lineage is most likely to take place after the TCRmediated selection. For the murine thymus, in which the Treg precursors have been located in the medullary CD4SP subset, a two-step model has been proposed. 31 In this scenario, the divergence to Treg cell lineage is dependent on TCR affinity, but the Treg phenotype is then stabilized by Both IL-2 and IL-7, nevertheless, suppressed cell death of FOXP3 + DP cells and upregulated the expression of the anti-apoptotic protein BCL-2. The effects of IL-15 on BCL-2 were less pronounced, and interestingly were observed in the CD3 low instead of the CD3 high subset.
Although preliminary, this suggests that the common gamma chain cytokines may, at least partly, exert their effects at distinct phases of Treg development. Another important consideration pertains to the availability of the common gamma chain cytokines to the developing thymocytes. IL-7 is produced by thymic epithelial cells in both cortex and medulla, and has been well established as an important cytokine already at the early stages of T cell development. 33, 34 Similarly, Caramalho et al 25 reported that IL-2 is expressed in both cortex and medulla, while IL-15 is secreted by macrophages and B cells throughout the thymus. Thus, the developing Treg cells are exposed to all 3 cytokines already at the DP stage. Our data, together with previous reports, thus support a two-step model for human Treg development, as well, with some differences compared with the murine scenario. 11, 25 In humans, Treg precursors are found already in the DP population, and TCR-mediated signals result in the positive selection of the FOXP3 + DP CD3 low cells and transition to the DP CD3 high stage, which already possesses suppressive capabilities. IL-15 may promote survival during this transition. The positively selected FOXP3 + cells then upregulate BCL-2 in response to IL-2 and IL-7, decrease the rate of proliferation, and migrate to the thymic medulla. The cytokines continue to influence the survival and proliferation of the medullary CD4SP Tregs; the exact contribution of cortical and medullary selection to the mature Treg population remains unclear.
